Oryzon Genomics' market value is the price at which a share of Oryzon Genomics trades on a public exchange. It measures the collective expectations of Oryzon Genomics SA investors about its performance. Oryzon Genomics is trading at 3.36 as of the 28th of December 2025. This is a No Change since the beginning of the trading day. The stock's lowest day price was 3.36. With this module, you can estimate the performance of a buy and hold strategy of Oryzon Genomics SA and determine expected loss or profit from investing in Oryzon Genomics over a given investment horizon. Check out Oryzon Genomics Correlation, Oryzon Genomics Volatility and Oryzon Genomics Alpha and Beta module to complement your research on Oryzon Genomics.
Please note, there is a significant difference between Oryzon Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oryzon Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oryzon Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Oryzon Genomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oryzon Genomics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oryzon Genomics.
0.00
11/28/2025
No Change 0.00
0.0
In 30 days
12/28/2025
0.00
If you would invest 0.00 in Oryzon Genomics on November 28, 2025 and sell it all today you would earn a total of 0.00 from holding Oryzon Genomics SA or generate 0.0% return on investment in Oryzon Genomics over 30 days. Oryzon Genomics is related to or competes with Open Orphan, Silence Therapeutics, Santhera Pharmaceuticals, Genfit SA, Transgene, Hansa Biopharma, and JW (Cayman). Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetic... More
Oryzon Genomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oryzon Genomics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oryzon Genomics SA upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oryzon Genomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oryzon Genomics' standard deviation. In reality, there are many statistical measures that can use Oryzon Genomics historical prices to predict the future Oryzon Genomics' volatility.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Oryzon Genomics. Your research has to be compared to or analyzed against Oryzon Genomics' peers to derive any actionable benefits. When done correctly, Oryzon Genomics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Oryzon Genomics SA.
Oryzon Genomics SA Backtested Returns
Oryzon Genomics SA maintains Sharpe Ratio (i.e., Efficiency) of close to zero, which implies the firm had a close to zero % return per unit of risk over the last 3 months. Oryzon Genomics SA exposes sixteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Oryzon Genomics' Risk Adjusted Performance of 0.0031, coefficient of variation of (65,973), and Variance of 1.45 to confirm the risk estimate we provide. The company holds a Beta of 0.38, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Oryzon Genomics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Oryzon Genomics is expected to be smaller as well. At this point, Oryzon Genomics SA has a negative expected return of -0.0018%. Please make sure to check Oryzon Genomics' risk adjusted performance, variance, as well as the relationship between the Variance and kurtosis , to decide if Oryzon Genomics SA performance from the past will be repeated at some point in the near future.
Auto-correlation
0.00
No correlation between past and present
Oryzon Genomics SA has no correlation between past and present. Overlapping area represents the amount of predictability between Oryzon Genomics time series from 28th of November 2025 to 13th of December 2025 and 13th of December 2025 to 28th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oryzon Genomics SA price movement. The serial correlation of 0.0 indicates that just 0.0% of current Oryzon Genomics price fluctuation can be explain by its past prices.
Correlation Coefficient
0.0
Spearman Rank Test
1.0
Residual Average
0.0
Price Variance
0.0
Oryzon Genomics SA lagged returns against current returns
Autocorrelation, which is Oryzon Genomics pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Oryzon Genomics' pink sheet expected returns. We can calculate the autocorrelation of Oryzon Genomics returns to help us make a trade decision. For example, suppose you find that Oryzon Genomics has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values
Timeline
Oryzon Genomics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Oryzon Genomics pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Oryzon Genomics pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Oryzon Genomics pink sheet over time.
Current vs Lagged Prices
Timeline
Oryzon Genomics Lagged Returns
When evaluating Oryzon Genomics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Oryzon Genomics pink sheet have on its future price. Oryzon Genomics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Oryzon Genomics autocorrelation shows the relationship between Oryzon Genomics pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Oryzon Genomics SA.
Other Information on Investing in Oryzon Pink Sheet
Oryzon Genomics financial ratios help investors to determine whether Oryzon Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oryzon with respect to the benefits of owning Oryzon Genomics security.